Markey Kate A
Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Medicine, University of Washington, Seattle, WA, USA.
Trends Immunol. 2024 Apr;45(4):231-233. doi: 10.1016/j.it.2024.03.004. Epub 2024 Mar 27.
Czech et al. used mouse models of allogeneic hematopoietic stem cell transplantation (allo-HCT) to investigate the role of lipocalin-2 (LCN2) as a newfound regulator of intestinal graft-versus-host disease (GVHD). Administration of recombinant LCN2 protein after disease onset prevented GVHD progression, suggesting that it may play a role in reversing tissue damage that has already begun.
捷克等人使用同种异体造血干细胞移植（allo-HCT）的小鼠模型，来研究脂质运载蛋白2（LCN2）作为一种新发现的肠道移植物抗宿主病（GVHD）调节因子的作用。疾病发作后给予重组LCN2蛋白可预防GVHD进展，这表明它可能在逆转已经开始的组织损伤中发挥作用。
